1
|
Sun ZG, Yao CJ, Ullah I, Zhu HL. Recent Advances in Natural Products with Anti-Leukemia and Anti- Lymphoma Activities. Mini Rev Med Chem 2024; 24:664-671. [PMID: 37855279 DOI: 10.2174/0113895575258798230927061557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 08/09/2023] [Accepted: 08/12/2023] [Indexed: 10/20/2023]
Abstract
Leukemia and lymphoma are the most common blood cancers, which pose a critical threat to the health of adults and children. The total incidence and mortality rates of both are approximately 6% globally. Compared with the expensive cost of CAR T cell therapy, natural products from animals, plants and microorganisms have the characteristics of wide-range sources and costeffectiveness in the treatment of cancer. Moreover, the drug resistance that emerged in leukemia and lymphoma treatments shows an urgent need for new drugs. However, in addition to the natural products that have been marketed in the treatment of leukemia and lymphoma, there have been a large number of studies on natural products that fight blood cancer in recent years. This review summarized the recent studies on natural compounds with anti-lymphoma and anti-leukemia activities, hoping to provide novel weapons into the drug development arsenal.
Collapse
Affiliation(s)
- Zhi-Gang Sun
- Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi, 276400, China
| | - Cheng-Jie Yao
- Yishui Juncheng Sika Deer Wildlife Research Institute, Longshan Guanzhuang Village, Mount Huangshan Pu Town, Linyi, 276400, China
| | - Inam Ullah
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Road, Nanjing, 210023, China
| | - Hai-Liang Zhu
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, No.163 Xianlin Road, Nanjing, 210023, China
| |
Collapse
|
2
|
Shen N, Yu Y, Zhang R, Guo Y, Liu M, Tan M, Liu J, Bai J, Li L, Liu K, Wang R, He J. Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma. Int J Clin Pract 2022; 2022:2637581. [PMID: 36567775 PMCID: PMC9750766 DOI: 10.1155/2022/2637581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 11/17/2022] [Accepted: 11/22/2022] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND To explore clinical features and prognostic value of vascular endothelial growth factor (VEGF), interleukin (IL) 8, IL-10, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and receptor-interacting protein-2 (RIP2) in diffuse large B-cell lymphoma (DLBCL). METHODS A total of 68 DLBCL patients admitted to the Affiliated Hospital of Hebei Engineering University from January 2017 to June 2021 were included in this retrospective analysis. Serum VEGF was detected by enzyme-linked immunosorbent assay, serum IL-8 and IL-10 were detected by chemiluminescent enzyme immunoassay, and expression of PIK3CA and RIP2 in tumors was detected by immunohistochemistry. The correlation between clinical features of DLBCL and tumor-related index were analyzed. Cox regression was conducted to explore risk factors and hazard ratio. RESULTS The serum level or expressions of VEGF, IL-8, IL-10, and RIP2 were significantly elevated with the increase of Ann Arbor Stage, International Prognostic Index (IPI) scores, Eastern Cooperative Oncology Group (ECOG) scores, serum lactate dehydrogenase (LDH) level, and the number of extranodal sites (all P < 0.05). Beside, these serum indexes were significantly higher in patients with the presence of extranodal involvement and germinal center B-cell (GCB), but significantly lower in patients with the presence of bone marrow involvement (all P < 0.05). Cox regression analysis for overall survival revealed that high expression of VEGF, high level of serum IL-8, serum IL-10, and RIP2, Ann Arbor Stage (III-IV), number of extranodal sites (>1), serum LDH level (≥245 U/L), IPI scores (3-5), ECOG scores (≥2), and bone marrow involvement were independent risk factors for the prognosis of DLBCL patients (all P < 0.05). CONCLUSION The serum levels of VEGF, IL-8, and IL-10, as well as the expression of RIP2 and PIK3CA in tumor tissues, were highly correlated to clinical features of DLBCL, and high expression level of these indexes may have adverse effects for the prognosis of DLBCL patients.
Collapse
Affiliation(s)
- Na Shen
- Department of Hematology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Yanfang Yu
- Department of Hematology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Ruiying Zhang
- Department of Hematology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Ying Guo
- Department of Science and Education, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Mei Liu
- Department of Science and Education, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Mengtian Tan
- Clinical School of Medicine, Hebei University of Engineering, Handan, Hebei, China
| | - Jianxia Liu
- Department of Quality Control, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Jing Bai
- Department of Geriatrics, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Li Li
- Department of Hematology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Keyu Liu
- Bone Marrow Laboratory, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Ran Wang
- Department of Emergency, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| | - Jinglan He
- Department of Orthopedics, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China
| |
Collapse
|
3
|
Tasso B, Spallarossa A, Russo E, Brullo C. The Development of BTK Inhibitors: A Five-Year Update. Molecules 2021; 26:molecules26237411. [PMID: 34885993 PMCID: PMC8659154 DOI: 10.3390/molecules26237411] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 12/04/2021] [Accepted: 12/05/2021] [Indexed: 01/14/2023] Open
Abstract
Bruton's tyrosine kinase (BTK) represented, in the past ten years, an important target for the development of new therapeutic agents that could be useful for cancer and autoimmune disorders. To date, five compounds, able to block BTK in an irreversible manner, have been launched in the market, whereas many reversible BTK inhibitors (BTKIs), with reduced side effects that are more useful for long-term administration in autoimmune disorders, are under clinical investigation. Despite the presence in the literature of many articles and reviews, studies on BTK function and BTKIs are of great interest for pharmaceutical companies as well as academia. This review is focused on compounds that have appeared in the literature from 2017 that are able to block BTK in an irreversible or reversible manner; also, new promising tunable irreversible inhibitors, as well as PROTAC molecules, have been reported. This summary could improve the knowledge of the chemical diversity of BTKIs and provide information for future studies, particularly from the medicinal chemistry point of view. Data reported here are collected from different databases (Scifinder, Web of Science, Scopus, Google Scholar, and Pubmed) using "BTK" and "BTK inhibitors" as keywords.
Collapse
|